Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705
Status:
Completed
Trial end date:
2007-07-25
Target enrollment:
Participant gender:
Summary
GSK233705 is being developed for the treatment of chronic obstructive pulmonary disease. This
will be an open-label, dose-ascending study in 7 healthy male subjects to establish well
tolerated intravenous doses and an oral dose of GSK233705. The main objective of the study is
to confirm an IV and oral dose for a definitive human radiolabel metabolic study.